This article is more than 5 years old. Information may no longer be current.

VIDEO: Ibandronate confers no significant benefit in early breast cancer

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SAN ANTONIO — Adam M. Brufsky, MD, PhD, offers insights on the TEAM IIb trial, presented at San Antonio Breast Cancer Symposium.

Results showed the addition of ibandronate (Boniva, Genentech) to adjuvant hormonal therapy conferred no significant benefit to postmenopausal women with early hormone receptor–positive breast cancer. However, results showed a trend toward longer DFS and less bone metastases.

“It looks like the trend in this study is consistent with other trials that showed small but clinically significant — even if not statistically significant — improvements in these women,” said Brufsky, co-director of the Comprehensive Breast Cancer Center at University of Pittsburgh and a HemOnc Today Editorial Board member. – by Kristie L. Kahl

Reference:

Linn S, et al. Abstract 6-02. Presented at: San Antonio Breast Cancer Symposium; Dec. 6-10, 2016; San Antonio, Texas.

Disclosure: Brufsky reports no relevant financial disclosures.